Anti-Covid-19 vaccination favors a decrease in cases in Cuba.

Havana, Cuba: The advance of mass vaccination against Covid-19 in Cuba favors the decrease in daily positive cases, hospitalizations and deaths, Prensa Latina publishes.

According to the Ministry of Health (Minsap), between 200 thousand and 300 thousand doses of Cuban own immunogens are administered daily, reaching 60.3 percent of the population (six million 748 thousand 348 people) with the complete scheme at the end of  October 16.

This includes convalescents from the disease who receive a single dose of Soberana Plus, developed by the Finlay Institute for Vaccines (IFV).

Nine million 704 thousand 167 people (86.8 percent) received at least one dose of Soberana 02, also from IFV, or Abdala, the latter designed by the Center for Genetic Engineering and Biotechnology (CIGB), while seven million 975 one thousand and one (71.3 percent) have the second injectable.

Likewise, they have three doses six million 482 thousand 926 people (58 percent) and to date 24 million 162 thousand 94 units have been administered.

The national director of Epidemiology of the Minsap, Francisco Durán, stressed that at this rate, the country will meet the goal of immunizing 90 percent of its inhabitants by the end of November.

He specified that the significant decrease in daily infections, hospitalized patients and deaths in the last week, figures lower than previous months, show the effect of this process.

The site Our World in Data, ranked the largest island of the Antilles in the first place with more than 80 percent of the total number of people who received at least one dose of vaccine against Covid-19, divided by the total population of the country, ahead of Canada, Italy, France, Japan, the United Kingdom, Germany and the United States.

The statistics correspond to the period from December 13, 2020 to October 14 of this year.

On the other hand, clinical trials are progressing with the immunogen Abdala and the vaccine candidate Mambisa, from the CIGB, as booster doses for convalescent patients who have not received any drug before or after the disease.

Phase II of this study will begin soon at the Hermanos Ameijeiras Clinical Surgical Hospital located in the capital for volunteers between 19 and 80 years of age, the scientific center announced.

According to official information, Mambisa is applied by means of a nasal spray, a drop dispenser or by means of a Cuban device with a syringe and it is a unique formulation of this type based on the platform of recombinantly produced antigens.

Por Redacción digital

Equipo de redactores del sitio web de Radio Mayabeque

Deja una respuesta

Tu dirección de correo electrónico no será publicada. Los campos obligatorios están marcados con *